Liebe Besucherinnen und Besucher,

aufgrund unseres Sommerfestes sind wir am 03. September 2026 bis 14 Uhr erreichbar. Am 04. September 2026 sind wir wieder wie gewohnt für Sie da. Vielen Dank für Ihr Verständnis.

Ihr Team von Sack Fachmedien

Shah / Imran / Ullah | Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy | Buch | 978-0-12-816773-1 | www.sack.de

Buch, Englisch, 310 Seiten, Format (B × H): 191 mm x 235 mm, Gewicht: 540 g

Shah / Imran / Ullah

Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy


Erscheinungsjahr 2019
ISBN: 978-0-12-816773-1
Verlag: Elsevier Inc

Buch, Englisch, 310 Seiten, Format (B × H): 191 mm x 235 mm, Gewicht: 540 g

ISBN: 978-0-12-816773-1
Verlag: Elsevier Inc


Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy reviews the principles and applications of nanocarriers for targeted drug delivery. Drug targeting involves active and passive strategies that exploit both the use of ligands for interactions and the physical and chemical properties of nanocarriers and micro-environments at target sites. Multidrug resistance and adverse side effects associated with anticancer drugs have attracted greater scientific attention and led formulation scientists to specifically target these drugs to target sites. Nanocarriers like liposomes, niosomes, gold nanorods, carbon nanotubes, and micelles are discussed for the delivery of drugs to specific disease sites.

This is an important reference source for researchers in the biomedical and biomaterials fields who want to gain an understanding on how nanotechnology is used for earlier diagnoses and more effective cancer treatment.

Shah / Imran / Ullah Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy jetzt bestellen!

Zielgruppe


materials scientists, biomedical scientists, bioengineers, and pharmaceutical scientists

Weitere Infos & Material


1. Potential physical and biological barriers leading to failure of cancer chemotherapy2. Nanotechnological strategies involved in the targeted delivery of anti-cancer drugs3. Liposome based targeted delivery of anticancer drugs and effective therapy of tumors4. Organic ligands as nanocarrier for targeted delivery of mediated active drug targeting for liver cancer5. Surface functionalized magnetic nanoparticles in cancer drugs delivery and diagnosis6. Nano-carriers based targeted pulmonary delivery: Novel approaches for effective lung cancer treatment7. Enhancing therapeutic efficacy of anticancer drugs through functionalized niosomes targeting8. Carbon nanotubes: Versatile nanocarriers for effective delivery of anti-cancer drugs9. Construction of stimulus responsive micelles systems for efficient targeting of cancer drugs10. Nano-targeted radiopharmaceuticals for cancer diagnosis and treatment11. Potential role of gold nanoparticles in cancer diagnosis and targeted drug delivery


Imran, Muhammad
Muhammad Imran is a graduate student and based at the International Center for Chemical and Biological Sciences, H.E.J. Research Institute of Chemistry University of Karachi, Pakistan.

Ullah, Shafi
Shafi Ullah is a graduate student and based at the International Center for Chemical and Biological Sciences, H.E.J. Research Institute of Chemistry University of Karachi, Pakistan.

Shah, Muhammad Raza
Prof. Muhammad Raza Shah is a professor and Director of the International Center for Chemical and Biological Sciences (ICCBS), University of Karachi, Pakistan. He holds four US patents. Dr. Shah has received numerous awards, including the Khwarizmi International Award from the Ministry of Science, Research and Technology, Iran (2023). He has also been honored with the Civil Award Tamgha-i-Imtiaz (2015), Dr. Raziuddin Prize (2015), Prof. Atta-ur-Rahman Gold Medal by the Pakistan Academy of Sciences, Avicenna Science & Innovation Award (2015) by Brain Trust UK, and the Abdus Salam Award in Chemistry (2006). He was named TWAS Young Affiliate in 2010 by The World Academy of Sciences. Prof. Shah is a Fellow of the International Union of Pure and Applied Chemistry, the Chemical Society of Pakistan, the Islamic World Academy of Sciences, and the Royal College of Physicians (Edinburgh). Dr. Shah has conducted 29 Phase-I (BE and PK) studies, 04 Phase-II Randomized Clinical Trial as PI and lead the Phase-I RCT of Sinopharm COVID-19 vaccine and Phase-III RCT of COVID-19 booster vaccine as country PI.



Ihre Fragen, Wünsche oder Anmerkungen
Vorname*
Nachname*
Ihre E-Mail-Adresse*
Kundennr.
Ihre Nachricht*
Lediglich mit * gekennzeichnete Felder sind Pflichtfelder.
Wenn Sie die im Kontaktformular eingegebenen Daten durch Klick auf den nachfolgenden Button übersenden, erklären Sie sich damit einverstanden, dass wir Ihr Angaben für die Beantwortung Ihrer Anfrage verwenden. Selbstverständlich werden Ihre Daten vertraulich behandelt und nicht an Dritte weitergegeben. Sie können der Verwendung Ihrer Daten jederzeit widersprechen. Das Datenhandling bei Sack Fachmedien erklären wir Ihnen in unserer Datenschutzerklärung.